Stephan Schann

Company: Domain Therapeutics
Job title: Chief Scientific Officer
Seminars:
CCR8: Great Expectations 1:15 pm
CCR8 is emerging as the next hot immuno-oncology target DT-7012: discovery of a highly differentiated anti-CCR8 depleting antibody DT-7012 is about to enter the clinicRead more
day: Conference Day Two